Enregistrement :
25
de
39
(2020-09-23
à
2021-02-01)
Politique ou Programme
Common Drug Review (CDR), with respect to health economics assessment and recommendations made on new medicines.
Federal Government Non Insured Health Benefits program with respect to reimbursement of a prescription medicine and changes in type of reimbursement
Public Health Agency of Canada, regarding the federal response to the hepatitis C virus.
Politique ou Programme, Proposition législative, Projet de loi ou résolution
Pharmaceutical intellectual property proposals that are part of the Comprehensive Economic and Trade Agreement with the European Union.
Politique ou Programme, Proposition législative, Projet de loi ou résolution, Règlement
Acts that propose to amend the Food and Drug Act and amendments to the Food and Drug Regulations related to the regulation of pharmaceuticals, biologic therapies, medical devices and foods.
Innovation, Science and Economic Development Canada (PMNOC) Regulations, as this relates to regulating intellectual property of prescription drugs; as well as discussions pertaining to growth and development of the life sciences industry in Canada, including as part of an Innovation Agenda.
Proposition législative, Projet de loi ou résolution, Règlement
Similar Entry Biologics (SEBs): requiring a Health Canada regulatory framework that support the approval of SEBs
Règlement
Patented Medicine Prices Review Board (PMPRB) Regulations.
with regard to prices charged by patentees for patented medicines sold in Canada.